Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333772 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL12847513 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL11223742 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL16217766 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15494655 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24771437 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL7147808 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20516514 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927890 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL3631711 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361990-B2 | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20120021046-A1 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2012-01-26 | — | — | US | claimed |
| US-20080020997-A1 | Glucosamine and Glucosamine/Anti-Inflammatory Mutual Prodrugs, Compositions, and Methods | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | claimed |
| EP-1742534-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005116086-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-20020128214-A1 | C-glucosyl ether lipids | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2002-09-12 | — | — | US | disclosed |
| EP-1181274-A1 | IMINOCYCLITOL INHIBITORS OF HEXOAMINIDASE AND GLYCOSIDASE | The Scripps Research Institute (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000068194-A1 | IMINOCYCLITOL INHIBITORS OF HEXOAMINIDASE AND GLYCOSIDASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-11-16 | — | — | WO | disclosed |
| US-5753631-A | Intercellular adhesion mediators | CYTEL CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5654412-A | CONVERGENT SYNTHESIS VIA TWO DISACCHARIDE SUBCOMPONENTS; SIMPLIFICATION, HIGH YIELD | GLYCOMED INCORPORATED (US) | 1997-08-05 | — | — | US | disclosed |
| US-5576305-A | Intercellular adhesion mediators | CYTEL CORPORATION (US) | 1996-11-19 | — | — | US | disclosed |
| US-5037969-A | Protein modifiers and fractionating agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0251304-A2 | Glycosyl derivatives and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128214-A1 | C-glucosyl ether lipids | UGCG, LIPC, UGGT1 | LMNA 776/4885KMT2A 3025/4885POLB 4703/4885 |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885POLB 3957/4885 |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2401/4885KMT2A 3992/4885POLB 4014/4885 |
| US-20120021046-A1 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | GNE, UGGT1, OGT | LMNA 2335/4885KMT2A 4647/4885POLB 2101/4885 |
| US-20080020997-A1 | Glucosamine and Glucosamine/Anti-Inflammatory Mutual Prodrugs, Compositions, and Methods | GNE, UGGT1, OGT | LMNA 2335/4885KMT2A 4647/4885POLB 2101/4885 |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | LMNA 3336/4885KMT2A 4576/4885POLB 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.